Progesterone induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in rats

Syed Suhail Andrabi¹, Suhel Parvez¹ and Heena Tabassum².*

ABSTRACT

Organelle damage and increases in mitochondrial permeabilization are key events in the development of cerebral ischemic tissue injury because they cause both modifications in ATP turnover and cellular apoptosis/necrosis. Early restoration of blood flow and improvement of mitochondrial function might reverse the situation and help in recovery following an onset of stroke. Mitochondria and related bioenergetic processes can be effectively used as pharmacological targets. Progesterone (P4), one of the promising neurosteroids, has been found to be neuroprotective in various models of neurological diseases, through a number of mechanisms. This influenced us to investigate the possible role of P4 in the mitochondria-mediated neuroprotective mechanism in an ischemic stroke model of rat. In this study, we have shown the positive effect of P4 administration on behavioral deficits and mitochondrial health in an ischemic stroke injury model of transient middle cerebral artery occlusion (tMCAO). After induction of tMCAO, the rats received an initial intraperitoneal injection of P4 (8 mg/kg body weight) or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 12 and 18 h. Behavioral assessment for functional deficits included grip strength, motor coordination and gait analysis. Findings revealed a significant improvement with P4 treatment in tMCAO animals. Staining of isolated brain slices from P4-treated rats with 2,3,5-triphenyltetrazolium chloride (TTC) showed a reduction in the infarct area in comparison to the vehicle group, indicating the presence of an increased number of viable mitochondria. P4 treatment was also able to attenuate mitochondrial reactive oxygen species (ROS) production, as well as block the mitochondrial permeability transition pore (mPTP), in the tMCAO injury model. In addition, it was also able to ameliorate the altered mitochondrial membrane potential and respiration ratio in the ischemic area, thereby suggesting that P4 has a positive effect on mitochondrial bioenergetics. In conclusion, these results demonstrate that P4 treatment is beneficial in preserving the mitochondrial functions that are altered in cerebral ischemic injury and thus can help in defining better therapies.

KEY WORDS: Progesterone, Cerebral ischemia, Neurobehavior, Mitochondria, Apoptosis, Neuroprotection

INTRODUCTION

Stroke is the leading global cause of death and disability as per reports by the World Heart Association (Avasarala et al., 2015). Ischemic stroke is the most common form of stroke, accounting for 87% of all types of strokes (Bennett et al., 2014). In spite of its high prevalence, no effective treatment is currently available that can alter the course of the disease. Tissue plasminogen factor (‘clot buster’) is the only FDA approved drug that is currently available for ischemic stroke patients, but has a narrow therapeutic time window (Peplow, 2015). Thus, there is a dire need for finding a new therapeutic strategy for stroke injury that has a prolonged treatment window.

Mitochondria play a crucial role in the pathophysiology of several neurological diseases, including stroke (Andrabi et al., 2015; Rasheed et al., 2017). Mitochondria are very susceptible to any insult, due to their critical role in energy metabolism, the production of reactive oxygen species (ROS), and apoptotic pathways (Waseem et al., 2016). The primary event in ischemia is disruption of the electron transport chain (ETC) due to the impaired delivery of oxygen and glucose (Novgorodov et al., 2016). The mitochondrial membrane potential (MMP), generated via proton transfer across the inner mitochondrial membrane for the production of adenosine triphosphate (ATP), is derailed in cerebral ischemia (Khatri and Man, 2013). Upon reperfusion, the damage becomes severe as a consequence of excess ROS accumulation in mitochondria, leading to attenuated activity of ETC components and favoring the open state of the mitochondrial permeability transition pore (mPTP) (Javadov and Kuznetsov, 2013). These pathological changes eventually cause the release of various apoptotic factors such as cytochrome c and apoptosis inducing factor (AIF), culminating in the initiation of an apoptosis cascade and eventually leading to cell death (Manzanero et al., 2013). Neurotransmitter-based excitotoxicity is another mechanism associated with ischemic injury (Lai et al., 2014). This excitatory neurotransmitter leads to cytosolic Ca²⁺ overload and mitochondrial swelling (Nicholls et al., 2015). This swelling causes mitochondrial permeabilization, releasing the apoptotic factors, including cytochrome c, and resulting in cell death in ischemia (Liu et al., 2009).

A large set of experimental evidence strongly supports the neuroprotective role of the steroid hormone progesterone (P4) in many CNS injury models (De Nicola et al., 2013). Additionally, preclinical data focused on the neuroprotective role of P4 in ischemic stroke through multiple mechanisms is available (Wong et al., 2013). In addition, clinical trials investigating the neuroprotective role of P4 have also been carried out in traumatic brain injury patients, making it an attractive pharmacological agent for the treatment of ischemic injury (Schumacher et al., 2015; Wright et al., 2014; Xiao et al., 2008). P4 can act multifunctionally by reducing oxidative damage, inhibiting apoptosis and regulating various signaling pathways in brain damage.
(Deutsch et al., 2013). However, the role of the mitochondria-mediated pathway in neuroprotection provided by P4 in ischemic stroke needs to be thoroughly explored before using it as a target-based therapy. Rodent models of cerebral ischemia are important tools in experimental stroke research. Such models have proven to be instrumental for the understanding of injury mechanisms in cerebral stroke as well as to identify potential new therapeutic options.

In the current study, we evaluated the mitochondria-mediated neuroprotective effects of P4, at clinically relevant concentrations, in vivo in the frontal cortex of a rodent model of cerebral ischemia established in our laboratory. We examined the effects of P4 on the extent of the infarction, the neurobehavioral outcome, and neurotransmitter levels in rats subjected to transient middle cerebral artery occlusion (tMCAO), an in vivo model of focal ischemia. Then, to elucidate its mitochondrial mechanism of action, we examined whether or not P4 could act by reducing Ca2+-induced mitochondrial swelling, an index of increased mitochondrial membrane permeability. In addition, we examined whether P4 could prevent the other mitochondrial functional changes, including loss of membrane potential, and alteration of and excess ROS production. To further prove our hypothesis, we analyzed mitochondrial bioenergetics by examining the state 3 respiratory control ratio (RCR) along with some ETC components. Finally, we examined the anti-apoptotic action of P4 by elucidating the translocation of cytochrome c from mitochondria to cytosol through the mPTP, and thereby authenticated our findings.

**RESULTS**

**Neurobehavioral analysis**

We studied several behavioral parameters to analyze the effect of P4 in attenuating the neurological deficits after (tMCAO) surgery. The first test involved scoring the grip strength between the sham, tMCAO and P4 administered groups. The mean reading of three successive trials for each rat was taken as a dependent variable. Grip strength decreased significantly (P<0.001) in rats subjected to tMCAO when compared to the sham group. Post hoc analysis showed that repeated administration of P4 [8 mg/kg body weight (b.w.)] improved the grip strength (P<0.05) at 24 h when compared to the tMCAO group (Fig. 1A). Next, we measured the riding time on the rotarod apparatus (in seconds) and mean of three successive trials for each rat was taken as a dependent variable. Grip strength decreased significantly (P<0.001) in rats subjected to tMCAO when compared to the sham group. This was followed by measurement of gait analysis to assess the gait impairment. ***P<0.001 versus sham, ##P<0.01 versus tMCAO (Fig. 1B). There was a significant (P<0.001) performance reduction in the tMCAO group when compared to the sham group. The one-way ANOVA and post hoc analysis showed that P4 improved the rotarod performance significantly (P<0.001) in the treated group compared with the tMCAO group. This was followed by measurement of gait analysis of animals, which utilizes calculation of stride length and stride width. Ischemic injury induced severe gait impairment in the tMCAO group (P<0.001) when compared to the sham group. This was improved significantly in P4 treated rats when stride length and stride width were evaluated after treatment (P<0.05-0.01) when compared to the tMCAO group (Fig. 1C,D).

**P4 modulates mitochondrial complexes after tMCAO**

Mitochondrial NADH dehydrogenase (complex I) plays a crucial role in the ETC for energy production and is deregulated in ischemic-injury-induced mitochondrial dysfunction. P4 treatment significantly (P<0.001) elevated the activity of NADH dehydrogenase in comparison to the tMCAO-only group, where a significant (P<0.001) decrease in complex I was seen when compared to the sham group (Fig. 3A). A similar pattern was observed for complex II, with a significant (P<0.01) increase in activity in the P4 group compared to the tMCAO group. For complex III, a significant (P<0.05) decrease in activity was observed in the tMCAO group compared to the sham group, and P4 treatment significantly (P<0.05) restored the activity to near normal levels. Complex IV activity was significantly (P<0.05) increased in the P4 group compared to the tMCAO group.

**P4 attenuates infarct volume after tMCAO injury**

In ischemic stroke models, TTC (2,3,5-triphenyltetrazolium chloride) staining is a fast and reliable visualization method for hypoxic brain tissue and dysfunctional mitochondria, and for defining the size of cerebral infarction. Brain slices from the P4-treated tMCAO group after 24 h were stained with TTC and showed a significant reduction in the infarct volume in comparison to the tMCAO rats (Fig. 2A,B).
observed when studying another ETC complex, succinate dehydrogenase (complex II), which transports electrons to quinone and is depleted by ischemic injury. The enzyme activity of complex II was significantly \((P<0.001)\) reduced in the tMCAO group when compared to the sham group (Fig. 3B). P4 administration significantly \((P<0.01)\) elevated the complex II activity in the treated group when compared to the tMCAO group. Furthermore, the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction rate (complex III) was used to assess the effect on the activity of the mitochondrial respiratory chain. P4 significantly \((P<0.01)\) improved the cell viability, while a significant \((P<0.001)\) decrease in cell viability in the tMCAO group was observed (Fig. 3C). Administration of P4 significantly \((P<0.01)\) restored the levels of complex V, while this was significantly \((P<0.001)\) decreased in the tMCAO group (Fig. 3D).

**Effect of P4 on mitochondrial oxidative stress parameters**

Lipid peroxidation (LPO) is one of the important biomarkers of oxidative damage. The level of mitochondrial LPO was significantly \((P<0.001)\) elevated in the tMCAO group and was significantly \((P<0.001)\) reduced with P4 treatment (Fig. 3E). Glutathione (GSH) is one of the most crucial non-enzymatic antioxidants involved in rescuing cells from oxidative damage. Mitochondrial GSH levels were found to be significantly \((P<0.01)\) restored with P4 treatment (Fig. 3F).

**P4 and mitochondrial bioenergetics**

We investigated the effect of P4 on mitochondrial oxygen consumption (state 3 respiration) and the RCR at 24 h after tMCAO. Results show that oxygen consumption and RCR was reduced \((P<0.05-0.01)\) in the frontal cortex of tMCAO animals when compared to the sham group. P4 at 8 mg/kg b.w. significantly \((P<0.05-0.01)\) restored the oxygen consumption as well as the RCR in the tMCAO P4 treated group when compared to the tMCAO alone group (Fig. 4A,B).

**P4 attenuates mitochondrial swelling**

P4 was able to bring down the levels of \(\text{Ca}^{2+}\)-induced mitochondrial swelling. There was no significant difference in light transmission between any groups before adding the \(\text{Ca}^{2+}\). The baseline value was...
taken for 5 min after addition of Ca\(^{2+}\) at the concentration of 400 µM. A significant \((P<0.001)\) decrease in light transmission in the tMCAO group occurred when compared to the sham group with addition of the Ca\(^{2+}\). This was significantly attenuated by P4 administration \((P<0.05)\) when compared to the tMCAO group (Fig. 4C).

**P4 reduces the mitochondrial ROS**

Mitochondrial ROS production was determined by 2′,7′-dichlorofluorescein (DCF) fluorescence. Measurement of ROS production in sham, tMCAO and tMCAO+P4 mitochondria was carried out as shown by changes in DCF fluorescence intensity (Fig. 5B). There was a significant \((P<0.001)\) increase in mitochondrial ROS level in the tMCAO group when compared to the sham group. P4 treatment effectively \((P<0.05)\) lowered the mitochondrial ROS level as shown by reduced DCF fluorescence intensity in comparison to the tMCAO group (Fig. 5C).

**Effect of P4 on MMP**

Changes in MMP in sham, tMCAO and tMCAO+P4 mitochondria was reflected by changes in TMRE fluorescence (Fig. 5D). There was a significant \((P<0.01)\) reduction in MMP as indicated by low fluorescence intensity in the tMCAO group when compared to the endogenously depolarized sham group. P4 significantly \((P<0.05)\) elevated the MMP as shown by high TMRE fluorescence intensity when compared to the tMCAO alone group (Fig. 5E).

**Effect of P4 on neurotransmitters**

P4 treatment significantly \((P<0.001)\) decreased the level of serotonin (5-HT) when compared to that of the tMCAO-only group. In the tMCAO group, the level of 5-HT was observed to be significantly \((P<0.001)\) raised when compared to the sham group (Fig. 6A). Also, a significant increase in dopamine level \((P<0.05)\) was observed after tMCAO when compared to that of the sham group. In P4 treated animals, dopamine levels were significantly \((P<0.01)\) lowered when compared to that of the tMCAO group (Fig. 6B).

**Effect of P4 on enzymatic neurotoxicity markers following tMCAO**

Monoamine oxidase (MAO) is an important neurotoxicity biomarker enzyme in the brain that catalyzes the breakdown of various monoamines. P4 significantly \((P<0.001)\) attenuated the level of MAO in the treatment group when compared to the tMCAO group. There was a significant \((P<0.001)\) elevation in only the tMCAO group (Fig. 6C) when compared to the sham group. Another prominent neurotoxicity marker includes the enzyme acetylcholine esterase (AchE), which is crucial for synaptic function.

---

**Fig. 5. Measurement of mitochondrial ROS and mitochondrial membrane potential (MMP).** (A) In the FSC/SSC plot of the isolated mitochondria, 10,000 events were collected within gate R1. (B) Measurement of ROS production in sham, tMCAO and tMCAO+P4 as shown by changes in DCF fluorescence. (C) The relative changes in DCF fluorescence intensity. \(***P<0.001\) versus sham, \(^{\#}P<0.05\) versus tMCAO. (D) Changes in MMP in sham, tMCAO and tMCAO+P4 as reflected by changes in TMRE fluorescence. (E) The relative changes in TMRE fluorescence intensity are shown. \(^{**}P<0.001\) versus sham, \(^{\#}P<0.05\) versus tMCAO. \(n=6\) in each group.

**Fig. 6. Effect of P4 on 5-HT, dopamine and neurotoxicity parameters.** (A) Effect of P4 on 5-HT. \(***P<0.001\) versus sham, \(###P<0.001\) versus tMCAO. (B) Effect of P4 on dopamine. \(^{*}P<0.05\) versus sham, \(##P<0.01\) versus tMCAO (\(n=6\) in each group). (C) Effect of P4 on monoamine oxidase activity. \(***P<0.001\) versus sham, \(###P<0.001\) versus tMCAO. (D) Effect of P4 on acetylcholine esterase activity. \(***P<0.001\) versus sham, \(^{\#}P<0.01\) versus tMCAO. (E) Effect of P4 on Na⁺ K⁺-ATPase. \(***P<0.001\) versus sham, \(^{\#}P<0.01\) versus tMCAO (\(n=6\) in each group).
termination of the nerve impulse by metabolism of acetylcholine. P4 administration significantly \( (P<0.01) \) lowered the activity of AchE in animals, in comparison to the tMCAO group. There was a significant \( (P<0.001) \) elevation of AchE enzyme level in the tMCAO group when compared to the sham group (Fig. 6D). Also, decreased levels of Na\(^+\) K\(^-\)-ATPase during brain injury indicated depletion of ATP. The same was lowered significantly \( (P<0.001) \) in the tMCAO group, when compared to the sham group. This was observed to be restored in P4 treated animals at a significant level \( (P<0.01; \text{Fig. } 6E) \) when compared to the tMCAO group.

**Histopathology**

The observed histological alterations included the presence of vacuolated spaces, pyknotic nuclei and heavy neuronal loss in the tMCAO group compared to the sham group. In the P4 treated tMCAO group, there was a reduction in vacuolation and neuronal loss as compared to the tMCAO-only group (Fig. 7A-C). Fig. 7D includes graphical representation of significant histological alterations in the tMCAO group \( (P<0.001) \) and the P4 treated group \( (P<0.05) \).

**Immunohistochemical analysis of cytochrome c translocation**

In the tMCAO group, the cytochrome c immunostaining was higher when compared to that in the sham group, thereby suggesting cytosolic translocation of cytochrome c. Treatment with P4 was able to reduce the translocation of cytochrome c following tMCAO (Fig. 8A-C). Cytosolic translocation of cytochrome c was found to be significantly \( (P<0.001) \) increased in tMCAO rats and its translocation was significantly inhibited \( (P<0.01) \) with P4 treatment. Quantitative measurements of cytosolic cytochrome c release are shown in Fig. 8D.

**DISCUSSION**

**Importance of the study**

In this study, we have investigated the potential mitochondrial mechanism underpinning the P4-enabled neuroprotection in a cerebral ischemia model with tMCAO. Based on the results obtained from evaluating alterations in various paradigms (such as mitochondrial permeability, MMP, ROS generation, and bioenergetics, including activity of ETC complexes in the frontal cortex of the brain), we can infer that mitochondrial dysfunction is one of the hallmarks of ischemia-reperfusion-induced cerebral damage leading to cellular death (Kalogeris et al., 2014). Hence, targeting mitochondria could be a promising neurotherapeutic tool (Jin et al., 2016). Blocking of the mPTP is already being considered to be one of the prime targets for protection in various neurological diseases (Fayaz et al., 2015). The main findings are: (1) P4 inhibited the formation of mPTP, eventually blocking the translocation of cytochrome c from mitochondria to cytosol; (2) P4 attenuated the tMCAO-induced production of mitochondrial ROS, rejuvenating the mitochondrial bioenergetics; and (3) P4 restored the activity of ETC components and various neurological functions.

**Behavioral outcomes**

We have performed a number of behavioral assays in rats to support the existence of neurological deficits/anomalies associated with the cerebral ischemic condition. Muscle weakness or motor impairment is a common complaint after stroke in humans. Our results have demonstrated that tMCAO leads to severe impairment in motor coordination, which was improved with P4 treatment. Also, abnormal changes occurred in grip strength and gait patterns of tMCAO animals, and these changes were also ameliorated by repeated P4 administration at the dose of 8 mg/kg b.w. These
observations are in agreement with previous findings of other research groups showing that P4 is able to improve motor coordination and various other neurological deficits (Yousuf et al., 2014). P4 treatment was also able to reduce the infarct size in animals, which can be associated with improvement of ischemia-induced neurological deficits.

Ischemia-induced neuronal death
Infarct volume is a crucial indicator of how severe the ischemic damage is; therefore, to confirm this, TTC staining was performed, which reliably identifies the infarct core. Only tMCAO-operated animals showed significant cortically lesioned areas, thereby indicating loss of dehydrogenase activity accompanied with increased presence of ROS in the region and probable secondary excitotoxicity (Drose et al., 2016). Another supporting cause might be the inhibition of blood supply to the injured area. This was attenuated by P4 administration post-occlusion, which can be attributed to its antioxidant, anti-apoptotic, and free-radical scavenging properties (Cai et al., 2015). It can also cross the blood–brain barrier, which might have helped it in reaching the injured brain region easily (Wang et al., 2009).

Oxidative stress causes mitochondrial dysfunction
Ischemia-induced production of ROS damages the various macromolecules and eventually may lead to cell death by apoptosis and necrosis. LPO, one of the oxidative stress markers, could lead to loss of mitochondrial membrane integrity and uncoupling of mitochondrial respiration, as was observed in our study and in a prior study by Rood and Hall (2000).

A loss of membrane integrity was observed 24 h after ischemia-reperfusion. It was accompanied by significant loss of endogenous antioxidant GSH, due to increased mitochondrial ROS as well as the compromised activity of ETC components. The change in DCF fluorescence intensity thus correlates linearly with the amount of intracellular ROS formed. Post-occlusion treatment with P4 significantly decreased the mitochondrial ROS as shown by reduction in fluorescence when compared to that of tMCAO-only rats. We assume that the antioxidant property of P4 might have helped in increasing the mitochondrial GSH content and providing protection against excess ROS (Gaignard et al., 2016). From these data, the pharmacological intervention targeting mitochondrial health seems to be a promising option for treating ischemic damage.

Due to mitochondrial LPO and oxidative stress, there was a loss of integrity of respirasomes (complexes I-V), which altered the efficacy of electron transport along the ETC (Lenaz et al., 2010). In ischemia-reperfusion, the primary event is the lack of oxygen and glucose as a result of a loss of blood supply, compromising the mitochondrial ETC complexes I-V/respirasomes (Sims and Muyderman, 2010; Sanderson et al., 2013). We made similar observations in the animals with tMCAO injury alone. P4 treatment after ischemic injury showed the elevated level of these complexes, suggesting a role of P4 in stabilizing the mitochondrial membrane.

Modulation of mPTP: a possible neuroprotective mechanism of P4
Ischemia-reperfusion-induced mitochondrial ROS production reduces the electron transfer kinetics, which eventually reduces the MMP. MMP and synthesis of ATP can reduce in ischemic stroke due to altered respirasomes and disturbed transport of protons across the inner mitochondrial membrane (Kalogeris et al., 2012). Flow cytometric monitoring of TMRE fluorescence demonstrated that ischemic insult resulted in a quick drop in MMP, visible as a strong decline in fluorescence intensity. This was significantly improved in the P4 treated group. Moreover, mitochondrial respiration also decreased due to ischemic injury as shown by decreased state 3 respiration and RCR. P4 significantly attenuated this deficit. P4, due to its anti-oxidative property, helps in preserving respirosome assembly by protecting the mitochondrial membrane from LPO (Aggarwal et al., 2008).

Mitochondrial swelling is one of the initial post-ischemic changes (Liang et al., 2013). In the present study, we measured mitochondrial swelling as an index of mitochondrial membrane permeabilization. After an ischemic injury, there was a significant increase in mitochondrial swelling, which modulates the mPTP and enables passage of cytochrome c from mitochondria to the cytosol, where it forms the apoptosome. This finding led to the presumption that P4 might have blocked the mPTP by binding to cyclosporine D. However, additional molecular studies need to be done to prove this finding. We further presume that, if P4 blocks mPTP, then translocation of cytochrome c from mitochondria to the cytosol must have been inhibited in P4 treated rats. To prove our hypothesis, we performed immunohistochemical analysis of translocation of cytochrome c from mitochondria to cytosol. The translocation was lowered after P4 administration and thus this finding strengthened our hypothesis that P4 might have blocked the mPTP. This novel finding sheds light on the mitochondrial protective and anti-apoptotic role of P4 that can be utilized therapeutically in stroke injury. A previous study on isolated mitochondria has also shown that P4 and its metabolite allopregnanolone inhibit the release of cytochrome c from mitochondria to cytosol (Sayeed et al., 2009).

Attenuation of neurotoxicity in ischemia by P4
We also studied the levels of brain-specific enzymes as a marker for neurotoxic damage due to ischemic injury. Alterations in the levels of these brain specific enzymes are one of the mechanisms behind neuronal cell death in ischemic stroke. Altered AchE activity and a disrupted cholinergic system play an important role in disturbed synaptic transmission and neuronal health in ischemic stroke (Kim and Kim, 2013). There was a significant elevation in AchE levels observed in tMCAO-only animals, and these were lowered with P4 administration. Studies have reported that AchE activity is increased by oxygen and nitrogen reactive species (Affonso et al., 2013). Considering that increased AchE activity has been related to progressive neurological decline and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, it is presumed that a disruption in the cholinergic system may be involved in the neurological deficit associated with the tMCAO model of stroke.

We also evaluated the effect on levels of MAO, which oxidises monoamines such as dopamine, 5-HT, and adrenaline (Wąsik et al., 2014). In aging and other neurodegenerative process, an increase in the activity of the mitochondrial enzyme MAO has been seen. MAO catalyses the oxidative deamination of various biogenic and xenobiotic amines, including the monoamine neurotransmitters 5-HT and dopamine, along with generating aldehydes and H2O2 (Weinreb et al., 2016). MAO inhibitors and antidepressants are most commonly used as a treatment for post-stroke depression in stroke patients (McCann et al., 2014). Ischemia-induced injury leads to excessive release of MAO that can lead to depression and anxiety. P4 treatment was able to reduce the excess MAO levels in the tMCAO group. Another
Changes in neurotransmitter levels affects the mitochondrial functions
This study also incorporated the analysis of neurotransmitters that play a crucial role in proper functioning of the nervous system. After the onset of ischemic stroke, cessation or reduction of blood flow to the brain induces neuronal damage. Monoamine neurotransmitters such as dopamine and 5-HT are important biogenic amines that are vital for transmitting nerve impulses for cognitive function of the body. Over-release of the above-mentioned neurotransmitters, which can be triggered by many types of neurotoxic insult, such as stroke, hazardous chemicals, tumors and neurodegenerative diseases, affect their respective receptors in the brain which can further induce cytotoxic responses, including altered calcium influx, free radical damage, oxidative stress, inflammatory responses and apoptosis, potentially leading to neuronal cell death and neurodegeneration (Chen et al., 2014).

Dopamine not only works as a neurotransmitter but acts as a good metal chelator and electron donor in in vivo conditions, generating toxic free radicals through the redox reaction. It has a high tendency to generate H₂O₂ through Fenton’s chemistry. This, in turn, causes mitochondrial respiratory chain breakdown and oxidative stress leading to cardiomyopathy and neurodegeneration (Uttara et al., 2009). 5-HT has an inhibitory effect on mitochondrial respiration, causing brain ATP depletion. It causes excitotoxic death of nerve cells, which involves both limitations of energy production and increased cellular activation (Chen et al., 2014). Levels of both of these neurotransmitters were found to be elevated in the tMCAO group and were attenuated by P4 treatment. P4 is known to possess specific anti-5-HT actions (Morton et al., 2015). P4 can attenuate neuronal excitotoxicity by blocking calcium channels or by upregulating inhibitory neurotransmitter GABA, which in turn can block the release of other excitatory neurotransmitters in the CNS (Wei and Xiao, 2013). Also, we have shown in the present study that P4 inhibits the activity of the enzyme MAO, which breaks down dopamine to generate toxic products such as H₂O₂, oxygen-derived radicals, semiquinones and quinones, leading to mitochondrial LPO and neurotoxic effects.

P4 improves anatomical damage in ischemic tissue

In this study, tMCAO-operated animals showed a series of histological alterations, including marked neurodegeneration with pyknotic neurons. P4 successfully ameliorated these histological alterations as observed by the reduced number of pyknotic neurons.

Conclusion
The current study adds further evidence that P4 is neuroprotective in cerebral ischemia. Our results indicate that P4 mediates its neuroprotection through mitochondrial pathways in male rats after cerebral ischemia. In conclusion, the results demonstrate that P4 was able to modulate the functional and cellular deficits associated with ischemic injury via mitochondrial pathways. It is important to assess potential neuroprotective candidates, such as P4, in the group at highest risk of stroke. As this study focused on mitochondrial pathways in male rats, further studies are warranted to study the effects on female rats.

MATERIALS AND METHODS

Animals and treatment regimen
Male Wistar rats (250-300 g) were obtained from the Central Animal House Facility of Jamia Hamdard, New Delhi, India. The animals were kept under a 12 h light-dark cycle with free access to food and water. Use of animals and all experimental procedures were conducted according to the procedures approved by the Animal Ethics Committee, Jamia Hamdard.

Experimental groups
The rats were divided randomly into three groups: (1) Sham-operated group, (2) tMCAO group, (3) tMCAO+P4 (8 mg/kg b.w.). The experimenter was blinded to the treatment group. All parameters were done in the frontal cortex of brain, and six animals were taken for each set of parameters in each group.

Surgical procedure

Focal tMCAO was performed according to the method of Vaibhav et al. (2013). Prior to tMCAO surgery, animals were anesthetized with chloral hydrate (460 mg/kg b.w.). A midline incision was made on the ventral surface of neck to expose the right common carotid artery. The external carotid artery (ECA) was ligated and internal carotid artery (ICA) was isolated near to the bifurcation. An intraluminal monofilament of filament size 4.0, length 30 mm, and diameter 0.19 mm having a silicon rubber-coated tip was introduced into the ECA and advanced through the ICA up to the origin of the middle cerebral artery (MCA). The suture was withdrawn slowly after 1 h occlusion of MCA, and rats were returned to their cages for the period of 23 h for reperfusion. In the sham group, ECA was surgically prepared but the filament was not inserted. Animals were returned to their normal environment in an air-conditioned room at an ambient temperature (25±2°C) and relative humidity (45-50%) with 12 h light/dark cycles and allowed free access to the pellet diet and purified drinking water.

P4 treatment

P4 (P-0130, Sigma-Aldrich Co.) at a dose of 8 mg/kg b.w. was dissolved in 50% dimethyl sulfoxide (DMSO) and 50% saline, which was administered by intraperitoneal (i.p.) injection 1 h post-occlusion followed subsequently (s.c.) at 6, 12, and 18 h post-occlusion. This dose is considered to be the dose for producing neuroprotection (Wali et al., 2014).

Behavioral tests

All naïve animals were given random training for 5 days for testing motor coordination, grip strength and gait pattern before the experiment in order to acclimatization and get a maximum possible score.

Assessment of motor impairment

To assess the sensorimotor coordination, the rats were evaluated in the rotarod task before sacrifice. In this study, motor function was assessed at 23 h post-occlusion by using a rotarod unit (Omni Rotor, Omnitech Electronics Inc., Columbus, OH, USA), which consists of a rotating rod of diameter 75 mm which is divided into four compartments to test four animals at a time (Ashafaq et al., 2012b). The time that each animal remains on the rotating rod was recorded for three trials with a minimum interval between each of 5 min and a maximum trial length of 180 s for each trial. The apparatus automatically recorded the time in tenths of a second until the rat falls to the floor. The speed was set at 10 rotations per minute and cut-off time was 180 s. The score was presented as mean of latencies of three trials on the rotating rod.

Assessment of grip strength

Grip test was performed by using the method of Ashafaq et al. (2012a). The apparatus consists of a string measuring about 50 cm in length, pulled tight between two vertical supports and elevated 40 cm from the flat surface. The rats were put on the string at midday and scoring was done according to the...
following scoring scale: 0=fall off, 1=hangs onto string by two forepaws, 2=hangs onto string by two forepaws and also tries to climb on string, 3=hangs onto string by two forepaws along with one or both hind paws, 4=hangs onto string by all forepaws along with tail wrapped around the string, 5=escape.

Gait analysis
The gait patterns were evaluated according to the previously published method (Ashafaq et al., 2012a) to find the gait-related anomalies at 24 h after tMCAO. Stride length and stride width were measured by using an enclosed wooden walkway of 12 cm width. The forepaws were stained with green non-poisonous coloring agent and hindpaws were stained with red color. Stride length was measured as the distance between ipsilateral forepaw and hindpaw. Stride width was taken as the side-to-side distance between the two forepaws, and the two hindpaws, respectively.

Measurement of infarction volume
The animals were sacrificed after 1 h of occlusion followed by 23 h of reperfusion (Ashafaq et al., 2016). The brains were dissected out and kept in a brain matrix. 1.5 mm coronal sections of the brains were cut down with the help of sharp blades and stained with 0.1% TTC prepared into normal saline at 37°C for 15 min. For imaging, the sections were scanned by a high-resolution scanner. The infarct volume was measured with ImageJ software.

Tissue collection and mitochondrial preparation
Mitochondria of brain frontal cortex of rat were isolated by the differential centrifugation method (Waseem and Parvez, 2016). Rats were decapitated and frontal cortex were dissected and homogenized by using a mechanically driven Teflon-fitted Potter-Elvehjem type homogenizer in ice-cold buffer A. Frontal cortical mitochondria were isolated in three buffers: A, B and C. Buffer A contained 250 mM sucrose, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM EGTA, and 0.1% fat-free BSA adjusted by Tris to pH 7.4 and centrifuged at 10,000 g for 10 min. Thereafter, the obtained pellet was resuspended and washed twice with washing medium (HEPES), 1 mM EGTA, and 0.1% fat-free BSA adjusted by Tris to pH 7.4 and centrifuged at 12,300 g for 10 min. Finally, the pellet was resuspended again in an isolation medium (C), containing 250 mM sucrose, 10 mM HEPES, and 0.1% fat-free BSA adjusted by Tris to pH 7.4 and centrifuged at 12,300 g for 10 min.

Mitochondrial complexes measurement
NADH dehydrogenase activity (complex I)
NADH dehydrogenase activity was assayed by spectrophotometrically according to Waseem and Parvez (2016). The enzyme activity was expressed as micromoles of NADH oxidized per minute per milligram protein using a molar extinction coefficient of 6.22×10^−5 M^−1 cm^−1.

Succinate dehydrogenase activity (complex II)
The activity of succinate dehydrogenase was assayed according to the method described by Waseem and Parvez (2016) by using the spectrophotometer. The enzyme activity was expressed as micromoles of succinate oxidized per minute per milligram protein using a molar extinction coefficient of 1000 M^−1 cm^−1.

Cytochrome c reductase (complex III)
Cytochrome c reductase activity was measured as described by Waseem and Parvez (2016). The results were expressed as micromoles of formazan formed per minute per milligram protein with a molar extinction coefficient of 51,000 M^−1 cm^−1.

F1-F0 synthase activity (complex V)
ATP synthase is also referred to as mitochondrial complex V. Its activity was assayed as hydrolysis of ATP into ADP plus inorganic phosphate (P_i) as described by Waseem and Parvez (2016). The enzyme activity was expressed as microgram of P_i liberated per minute per milligram protein.

Assessment of oxidative stress damage
Mitochondrial LPO was assayed according to the procedure of Chaudhary and Parvez (2012) with certain modifications. The results were expressed as nanomoles of thiobarbituric acid-reactive substances (TBARS) formed per hour per gram tissue using a molar extinction coefficient of 1.56×10^−5 M^−1 cm^−1. GSH concentration in brain mitochondria was measured according to the method of Tabassum et al. (2007). The GSH content was calculated as nanomoles of GSH reduced per gram tissue.

Mitochondrial respiration measurement
Mitochondrial oxygen consumption was measured by using a Clark-type oxygen electrode (Hansatech Instrument) (Waseem and Parvez, 2016) at 37°C pH 7.4 in a KCl medium containing 0.1 mM EDTA, MgCl2, sucrose and KH2PO4. Rats were sacrificed 24 h after tMCAO and frontal cortex was isolated for mitochondrial preparations. Mitochondrial respiratory energy coupling was evaluated by determining respiratory control ratio (RCR) calculated as the rate of ADP-induced state 3 respiration to the state 4 rate without ADP. The rate of mitochondrial respiration was measured as nanomoles of oxygen (O2) min/mg of protein.

Mitochondrial swelling
Mitochondrial swelling caused by the influx of solutes through open permeability transition pores results in an increase in light transmission (i.e. a reduced turbidity). This turbidity change offers a convenient and frequently used assay of the mitochondrial permeability transition by measurement of absorbance in mitochondrial suspensions. Mitochondrial permeability was assayed by Ca2+-induced mitochondrial swelling and was assayed by spectrophotometry (Li et al., 2012). The mitochondrial pellet was re-suspended in ice-cold BSA-free and EDTA-free sucrose buffer after the last step of washing (300 mmol sucrose and 10 mmol/l Tris-base, pH 7.4). The aliquot of 100 µg of mitochondria was added to 1 ml of BSA-free and EDTA-free buffer and 400 µm Ca2+ was added after 5 min and reading was taken for 5 min at 540 nm.

Flow cytometric analysis of MMP and mitochondrial ROS
Flow cytometry analysis was performed using a FACS Calibur equipped with a 488 nm argon laser and a 635 nm red diode laser according to Li et al. (2012). Data from the experiments were analyzed using the CellQuest software (BD Bioscience). To exclude debris, samples were gated based on light scattering properties in the side scattering (SSC) and forward scattering (FSC) modes, and 10,000 events per sample within the R1 gate were collected. The mitochondrial sample was suspended in analysis buffer containing 250 mmol/l sucrose, 20 mmol/l MOPS, 10 mmol/l Tris-base, 100 µmol/l Pi(K), and 0.5 mmol/l Mg2+ and 5 mmol/l succinate at pH 7.4. The mitochondria were then stained with TMRE (100 nmol/ml, excitation at 488 nm and emission at 590 nm) and H2DCFDA (2, 7 dichloro dihydro fluorescein diacetate) (10 mmol/l, excitation at 488 nm and emission at 525 nm), which were used to measure the MMP and the production of ROS, respectively.

Neurotransmitter detection using HPLC
Estimation of 5-HT and dopamine in the brain frontal cortex was done using high-performance liquid chromatography (HPLC)-electrochemical detection (ECD) by the method of Chaudhary and Parvez (2012). Chromatographic analyses were performed at room temperature. Data were acquired and processed in the Empower Pro Operating System. 5-HT peaks were identified by comparing their retention time in the sample and its concentration was estimated according to the area under the curve using the straight line equation y=mx+c. Dopamine concentration was represented as ng/mg protein.

Neuronal insult markers
MAO was measured according to the method reported by Vishnoi et al. (2015). The enzyme activity was assayed as nanomoles of benzyl amine hydrochloride (BAHC) hydrolyzed per minute per milligram protein using a molar extinction coefficient of 7.6925 M^−1 cm^−1. AchE was estimated according to the method of Vishnoi et al. (2015). The enzyme activity was
measured as nmoles of acetyl thiocholine (ATC) hydrolyzed/min/mg protein using a molar extinction coefficient of $1.36 \times 10^4$ M$^{-1}$ cm$^{-1}$. Na$^+$ K$^+$-ATPase activity was measured according to the method developed by Chaudhary and Parvez (2012). The activity was measured as $\mu$g of P liberated/min/mg protein.

**Histology**

After performing neurobehavioral tests, animals were deeply anesthetized intraperitoneally with chloral hydrate (400 mg/kg b.w.) at 24 h after ischemia-reperfusion and were transcardially perfused through the ascending aorta with 0.9% saline according to the method of Ashafaq et al. (2012a). This was followed by ice-cold buffered 4% paraformaldehyde and then the brain was removed and put in paraformaldehyde for 48 h. Brain removal was followed by dehydration with ethanol. It was then embedded in paraffin then coronal sections (40 μm thick) were taken for hematoxylin and cosin staining. Histopathological scoring was done with the aid of a pathologist in our animal house. Scoring was done on the basis of morphological changes in the frontal cortex. According to the morphological changes, sections were given scores as follows: 0 (no change), 1 (minor changes), 2 (vacuolated spaces), 3 (pyknotic nuclei), 4 (vacuolated spaces and pyknotic nuclei), 5 (heavily neuronal loss).

**Cytochrome c**

Immunohistochemical analysis was performed according to the method of Vishnoi et al. (2015), with some modifications. The brain was removed and fixed in 4% paraformaldehyde. Brain sections were cut from paraffin-embedded, paraformaldehyde-fixed brain tissue and mounted on poly-L-lysine-coated microscopic slides. Sections were deparaffinized three times (5 min) in xylene followed by dehydration in graded ethanol and finally rehydrated in running tap water. For antigen retrieval, sections were boiled in 10 mM citrate buffer (pH 6.0) for 10-15 min. Sections were incubated with hydrogen peroxide for 15 min to minimize non-specific staining and then rinsed three times (5 min each) with PBS (0.05% Tween-20). Blocking solution was applied for 10 min, then sections were incubated with primary antibody. The anti-cytochrome c antibody mouse monoclonal (dilution 1:200, Calbiochem®, cat. #QA87) overnight at 4°C in a humid chamber. The anti-cytochrome c antibody is a mouse monoclonal (isotype IgG2b) that reacts with human, mouse and rat cytochrome c. The next day, the slides were washed with PBS three times and were incubated with secondary antibody goat anti-mouse IgG for 2 h. The peroxidase complex was visualized with 3,3-diaminobenzidine (DAB). Next, the slides were counterstained with hematoxylin and dried. Finally, the sections were mounted with dibutylphthalate polystyrene xylene and covered with coverslips. The slides were then ready to be observed under the microscope. The intensity of the cytosolic immunostaining protocol was used for quantitative evaluation of immunostaining. Measurements were carried out using an inverted light microscope using objectives with 40× magnifications. Quantification of immunohistochemistry slides was performed by ImageJ 1.44 V (Wayne Rasband National Institute of Health, USA).

**Determination of protein**

Protein contents in different fractions (supernatant, homogenate and mitochondria) of the brain frontal cortex were assayed by the Bradford method using BSA as a standard.

**Statistical analysis**

All data are shown as mean±standard error of mean (s.e.m.). All data were analyzed by using analysis of variance (ANOVA) followed by Tukey’s test. All data were analyzed by using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). Values of $P<0.05$ were considered significant.

**Competing interests**

The authors declare no competing or financial interests.

**Author contributions**

Conceptualization: S.P., H.T.; Methodology: S.S.A., H.T.; Software: S.P., H.T.; Validation: S.P., H.T.; Formal analysis: H.T.; Investigation: S.S.A., S.P., H.T.; Resources: H.T.; Data curation: S.P., H.T.; Writing - original draft: S.S.A., S.P., H.T.; Writing - review & editing: H.T.; Visualization: H.T.; Supervision: S.P., H.T.; Project administration: S.P., H.T.; Funding acquisition: S.P., H.T.;

**Funding**

This work was funded by the Department of Biotechnology, Ministry of Science and Technology, Government of India, for the financial grant (DBT Biocrates Program, sanction no. BT/BRICS-2010/10219/2015-14 to H.T.); Science and Engineering Research Board (SERB-EMR grant no. 2016/001070/H.S.P.S.S.A. is a recipient of a Senior Research Fellowship from University Grants Commission-Basic Science Research (UGC-BSR) [grant no. F.25-1/2013-14(BSR)/7-91/2007(BSR)].

**References**

Andrabi, S. S., Parvez, S. and Tabassum, H. (2015). Melatonin and ischemic stroke: mechanistic roles and action. Adv. Pharmacol. Sci. 2015, 384750.

Ashafaq, M., Khan, M. M., Shadab Raza, S., Ahmad, A., Khwaja, G., Javed, H., Khan, A., Islam, F., Siddiqui, M. S., Safhi, M. M. et al. (2012a). S-allyl cysteine mitigates oxidative damage and improves neurologic deficit in a rat model of focal cerebral ischemia. Nutr. Res. 32, 133-143.

Ashafaq, M., Raza, S. S., Khan, M. M., Ahmad, A., Javed, H., Ahmad, M. E., Tabassum, R., Islam, F., Siddiqui, M. S., Safhi, M. M. et al. (2012b). Catechin hydrate ameliorates redox imbalance and limit inflammatory response in focal cerebral ischemia. Neurochem. Res. 37, 1747-1760.

Ashafaq M, Tabassum, H. and Parvez, S. (2016). Modulation of behavioral deficits and neurodegeneration by tannic acid in experimental stroke challenged Wistar rats. Mol. Neurobiol.

Avasarala, J. (2015). Letter “2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 46, e234.

Bennett, D. A., Krishnamurthi, R. V., Barber-Collo, S., Forouzanfar, M. H., Naghavi, M., Connor, M., Lawes, C. M. M., Moran, A. E., Anderson, L. M., Roth, G. A. et al. (2014). The global burden of ischemic stroke: findings of the GBD 2010 study. Glob. Heart 9, 107-112.

Cai, J., Cao, S., Chen, J., Yan, F., Chen, G. and Dai, Y. (2015). Progesterone alleviates acute brain injury via reducing apoptosis and oxidative stress in a rat experimental subarachnoid hemorrhage model. Neurosci. Lett. 600, 238-243.

Chaudhary, S. and Parvez, S. (2012). An in vitro approach to assess the neurotoxicity of valproic acid-induced oxidative stress in cerebellum and cerebral cortex of young rats. Neurotoxicology 31, 268-276.

Chen, Y., Garcia, G. E., Huang, W. and Constantini, S. (2014). The involvement of secondary neuronal damage in the development of neurodegenerative disorders following brain insults. Front. Neuro. 5, 22.

de Lores Arnaiz, G. R. and Ordieres, M. G. (2014). Brain Na(+), K(+)-ATPase activity in aging and disease. Int. J. Biochem. Cell. Biol. 10, 85-102.

De Nicola, A. F., Coronel, F., Garay, L. I., Gargiulo-Monachelli, G., Gonzalez Deniselle, M. C., Gonzalez, S. L., Labombarda, F., Meyer, M., Guennoun, R. and Schumacher, M. (2013). Therapeutic effects of progesterone in animal models of neurodegenerative disorders. CNS Neurol. Disord. Drug Targets 12, 1205-1218.

Deutsch, E. R., Espinoza, T. R., Atif, F., Woodall, E., Kaylor, J. and Wright, D. W. (2013). Progesterone’s role in neuroprotection, a review of the evidence. Brain Res. 1530, 82-105.

Drose, S., Stépanova, A. and Galkin, A. (2016). Ischemic AICD transition of mitochondrial complex I and its role in ROS generation. Biochim. Biophys. Acta 1857, 946-957.

Fayaz, S. M., Raj, Y. V. and Krishnamurthy, R. G. (2015). CypD: the key to the death door. CNS Neurol. Disord. Drug Targets 14, 654-663.

Gaignard, P., Fréchou, M., Schumacher, M., Thérand, P., Mattern, C., Slama, A. and Guennoun, R. (2016). Progesterone reduces brain mitochondrial dysfunction after transient focal ischemia in mice and female mice. J. Cereb. Blood Flow Metab. 36, 562-568.

Javadov, S. and Kuznetsova, A. (2013). Mitochondrial permeability transition and cell death: the role of cyclophilin d. Front. Physiol. 4, 76.

Jin, Z., Wu, J. and Yan, L.-J. (2016). Chemical conditioning as an approach for ischemic stroke tolerance: mitochondria as the target. Int. J. Mol. Sci. 17, 351.

Kalogeris, T., Baines, C. P., Krenz, M. and Korthuis, R. J. (2012). Cell biology of ischemia/reperfusion injury. Int. Rev. Cell Mol. Biol. 298, 229-317.

Kalogeris, T., Bao, Y. and Korthuis, R. J. (2014). Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox. Biol. 2, 702-714.
Khatri, N. and Man, H.-Y. (2013). Synaptic activity and bioenergy homeostasis: implications in brain trauma and neurodegenerative diseases. Front. Neurol. 4, 199.

Kim, G., Kim, E. (2013). Effects of treadmill training on limb motor function and antioxidative polyphenol in rats with stroke. J. Phys. Ther. Sci. 25, 1227-1230.

Lai, T. W., Zhang, S. and Wang, Y. T. (2014). Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog. Neurobiol. 115, 157-188.

Lenaz, G., Baracca, A., Barbero, G., Bergamini, C., Dalmonte, M. E., Del Sole, M., Faccioli, M., Falsacasa, A., Fato, R., Genova, M. L. et al. (2010). Mitochondrial respiratory chain super-complex I-III in physiology and pathology. Biochim. Biophys. Acta 1797, 633-640.

Li, J., Ma, X., Yu, W., Lou, Z., Mu, D., Wang, Y., Shen, B. and Qi, S. (2012). Reperfusion promotes mitochondrial dysfunction following focal cerebral ischemia in rats. PLoS ONE 7, e46498.

Liang, J.-M., Xu, H.-Y., Zhang, X.-J., Li, X., Zhang, H.-B. and Ge, P.-F. (2013). Role of mitochondrial function in the protective effects of ischaemic postconditioning on ischaemia/reperfusion cerebral damage. J. Int. Med. Res. 41, 618-627.

Liu, Y., Liu, X.-J. and Sun, D. (2009). Ion transporters and ischemic mitochondrial dysfunction. Cell Adh. Migr. 3, 94-98.

Manzanero, S., Santro, T. and Arumugam, T. V. (2013). Neuronal oxidative stress in acute ischemic stroke: sources and contribution to cell injury. Neurochem. Int. 62, 712-718.

McCann, S. K., Irvine, C., Mead, G. E., Sena, E. S., Currie, G. L., Egan, K. E., Macleod, M. R. and Howells, D. W. (2014). Efficacy of antidepressants in animal models of ischemic stroke: a systematic review and meta-analysis. Stroke 45, 3055-3063.

Martina, R. A., Yanagawa, Y. and Valenzuela, C. F. (2015). Electrophysiological assessment of serotonin and GABA neuron function in the dorsal raphe during the third trimester equivalent developmental period in mice. eNeuro 2, 1-14.

Nicholls, D. G., Brand, M. D. and Gerencser, A. A. (2015). Mitochondrial bioenergetics and neuronal survival modelled in primary neuronal culture and isolated nerve terminals. J. Bioenerg. Biomembr. 47, 63-74.

Novgorodov, S. A., Riley, C. L., Keffer, J. A., Yu, J., Kindy, M. S., Macklin, W. B., Lombard, D. B. and Gudz, T. I. (2016). SIRT3 deacetylases cereamide synthases: implications for mitochondrial dysfunction and brain injury. J. Biol. Chem. 291, 19587-19597.

Peplow, P. V. (2015). Neuroimmunomodulatory effects of transcranial laser therapy combined with intravenous tPA administration for acute cerebral ischemic injury. Cell. Mol. Neurobiol. 35, 697-711.

Rasheed, M. Z., Tabassum, H. and Parvez, S. (2017). Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson’s disease. Protoplasma 254, 33-42.

Roof, R. L., Hall, E. D. (2000). Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J. Neurotrauma 17, 367-388.

Sanderson, T. H., Reynolds, C. A., Kumar, R., Przyklenk, K., Hüttmann, M. (2013). Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol. Neurobiol. 47, 9-23.

Sayed, I., Parvez, S., Wali, B., Siemen, D. and Stein, D. G. (2009). Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res. 1263, 165-173.

Schumacher, M., Denier, C., Oudinet, J.-P., Adams, D. and Guennoun, R. (2015). Progesterone neuroprotection: the background of clinical trial failure. J. Steroid Biochem. Mol. Biol. 160, 53-66.

Sims, N. R., Muyderman, H. (2010). Mitochondria, oxidative metabolism and cell death in stroke. Biochim. Biophys. Acta 1797, 633-640.

Tabassum, H., Parvez, S., Rehman, H., Dev Banerjee, B., Siemen, D. and Raisuddin, S. (2007). Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice. Hum. Exp. Toxicol. 26, 509-518.

Uttara, B., Singh, A. V., Zamboni, P. and Mahajan, R. T. (2009). Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7, 65-74.

Vaibhav, K., Shrivastava, P., Tabassum, R., Khan, A., Javed, H., Ahmed, M. E., Islam, F., Safi, M. M. and Islam, F. (2013). Delayed administration of zingiberone mitigates the behavioral and histological alteration via repression of oxidative stress and intrinsically programmed cell death in focal transient ischemic rats. Pharmacol. Biochem. Behav. 113, 53-62.

Vishnoi, S., Raisuddin, S. and Parvez, S. (2015). Modulatory effects of an NMDAR partial agonist in MK-801-induced memory impairment. Neuroscience 311, 22-33.

Wall, B., Istrat, T., Won, S., Stein, D. G., Sayeed, I. (2014). Progesterone in experimental permanent stroke: a dose-response and therapeutic time-window study. Brain 137, 486-502.

Wang, J., Jiang, C., Li, X., Liu, C., Cheng, N. and Hao, Y. (2009). The protective mechanism of progesterone on blood-brain barrier in cerebral ischemia in rats. Brain Res. Bull. 79, 426-430.

Waseem, M. and Parvez, S. (2016). Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxalipatin. Protoplasma 253, 417-430.

Waseem, M., Tabassum, H. and Parvez, S. (2016). Melatonin modulates permeability transition pore and 5-hydroxydecanoate induced KATP channel inhibition in isolated brain mitochondria. Mitochondrion 31, 1-8.

Wąsik, A., Mozdżer, E., Michaluk, J., Romanińska, I. and Antkiewicz-Michaluk, L. (2014). 1-Methyl-2,3,4-trihydroxybenzoquinone, an endogenous Neuroprotectant and a novel inhibitor with antidepressant-like properties in the rat. Neurotoc. Res. 25, 323-334.

Wei, J. and Xiao, G.-M. (2013). The neuroprotective effects of progesterone on traumatic brain injury: current status and future prospects. Acta Pharmacol. Sin. 34, 1485-1490.

Weinreb, O., Amil, T., Bar-Am, O. and Youdim, M. B. H. (2016). Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer’s disease. Br. J. Pharmacol. 173, 2080-2094.

Wong, R., Renton, C., Gibson, C. L., Murphy, S. J., Kendall, D. A. and Bath, P. M. W. (2013). Progesterone treatment for experimental stroke: an animal model of Parkinson's disease. Cereb. Blood Flow Metab. 33, 1362-1372.

Wright, D. W., Yeatts, S. D., Silbergleit, R., Palesch, Y. Y., Hertzberg, V. S., Frankel, M., Goldstein, F. C., Caveney, A. F., Howlett-Smith, H., Bengelink, E. M. et al. (2014). Every early administration of progesterone for acute traumatic brain injury. N. Engl. J. Med. 371, 2457-2466.

Xiao, G., Wei, J., Yan, W., Wang, W. and Lu, Z. (2008). Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 12, R61.

Youssef, S., Sayeed, I., Atif, F., Tang, H., Wang, J. and Stein, D. G. (2014). Delayed progesterone treatment reduces brain infarction and improves functional outcomes after ischemic stroke: a time-window study in middle-aged rats. J. Cereb. Blood Flow Metab. 34, 297-306.